Ashkan M. Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy
At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.
Stay updated with breaking news from Month Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial will be presented at the upcoming 50th Annual VEITH...
BEIJING, May 21 (Xinhua) -- China solar power generation increased in April amid the country clean energy push, official data showed. Solar power generation exp
uniQure Inc.: uniQure to Participate in Multiple Upcoming Industry Conferences in June ~ uniQure to host virtual Research & Development Day on June 22, 2021 ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2021(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Jefferies Virtual Healthcare Conference, June 1 - 4, 2021 Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the d...